We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 30, 2020

Apatinib Plus Chemotherapy as Second-Line Treatment in Unresectable NSCLC

The Oncologist


Additional Info

The Oncologist
Apatinib Plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial
Oncologist 2020 Jun 13;[EPub Ahead of Print], Z Yu, Z Xu, Z He, J Lai, W Wang, J Zhang, W Kong, X Huang, Y Chen, Y Shi, X Shi, Z Zhao, M Ni, X Lin, S Chen, X Wu, W Chen, Z Song, C Huang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading